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ABSTRACT 
Cognitive Stimulation Therapy (CST) is widely used with people with dementia, but there is 
no evidence of its efficacy in mild cognitive impairment or dementia in Parkinson’s disease 
(PD-MCI; PDD) or dementia with Lewy bodies (DLB). We aimed to explore the impact of 
‘CST-PD’, which is home-based, individualised CST adapted for this population. In a single-
blind randomised controlled exploratory pilot trial (RCT), we randomised 76 participant-dyads 
(PD-MCI (n=15), PDD (n=40), DLB (n=21) and their care partners) to CST-PD or treatment-
as-usual (TAU). CST-PD involves home-based cognitively stimulating and engaging activities 
delivered by a trained care partner. Exploratory outcomes at 12 weeks included cognition 
(Addenbrooke’s Cognitive Evaluation; ACE-III), neuropsychiatric symptoms and function. In 
care partners, we assessed burden, stress and general health status. Relationship quality and 
quality of life were assessed in both dyad members. At 12 weeks, the ACE-III showed a non-
statistically significant improvement in the CST-PD group compared to the TAU group, 
although neuropsychiatric symptoms increased significantly in the former. In contrast, care 
partners’ quality of life (d = 0.16) and relationship quality (‘satisfaction’, d=0.01; ‘positive 
interaction’, d = 0.55) improved significantly in the CST-PD group, and care burden (d = 0.16) 
and stress (d = 0.05) were significantly lower. Qualitative findings in the CST-PD recipients 
revealed positive ‘in the moment’ responses to the intervention, supporting the quantitative 
results. In conclusion, care partner-delivered CST-PD may improve a range of care partner 
outcomes, which are important in supporting home-based care. A full-scale follow-up RCT to 
evaluate clinical and cost-effectiveness is warranted.  
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INTRODUCTION 
Disorders of cognitive impairment within the Lewy body spectrum of diseases include mild 
cognitive impairment in Parkinson’s disease (PD-MCI), dementia due to Parkinson’s disease 
(PDD) and dementia with Lewy bodies (DLB). Together, DLB and PDD constitute over 15%1 
of total dementias and PD-MCI occurs in about 25% of people with Parkinson’s disease (PD).2,3 
PDD and DLB are associated with significant impairments in cognition, quality of life and high 
levels of disability and care partner burden.4 Treatment options focus on pharmacological 
approaches, which have modest effectiveness and may often not be tolerated by frail people 
with dementia in the context of a movement disorder. Thus, there is scope for non-
pharmacological interventions that are specifically adapted for people with cognitive 
impairment or dementia within the Lewy body spectrum.5 To date, only one other study of a 
psychosocial intervention in PDD has been conducted, and this study examined the impact of 
goal-oriented cognitive rehabilitation therapy.6 This small study found positive outcomes self-
rated goal attainment, mood, and quality of life in those receiving the active intervention 
compare to relaxation therapy and ‘treatment as usual’. 
 
Cognitive Stimulation Therapy (CST) is an evidence-based psychosocial intervention that 
involves engaging and cognitively-stimulating activities and discussions based on principles of 
errorless learning and validation.7,8 As demonstrated by meta-analyses, CST improves 
cognition and quality of life in people with different forms of dementia, and improves 
outcomes, such as quality of life, for care partners.9,10 In people with PDD, only one study has 
evaluated CST.11 This was a small pilot cross-over trial (n=12) of people living in a care home 
setting. It found that group CST (offered eight weeks, twice weekly for 60 minutes), adapted 
for PDD, is feasible and potentially effective for cognitive and non-cognitive outcomes in PDD, 
compared to ‘treatment as usual’.   
 
We undertook an iterative development process to adapt the individualised form of CST (iCST) 
specifically for people with PD-MCI/PDD/DLB to be delivered by their care partners at home 
(PD-CST).12 PD-CST differs from professionally delivered group-based CST, in that PD-CST 
can be delivered at home by a trained care partner and can be tailored more easily to the specific 
needs and capabilities of the recipient. Here we report the results of an exploratory pilot study 
of the impact of PD-CST on recipients of the intervention and their care partners. In addition, 
we evaluated the acceptability of the intervention and the feasibility of conducting a full-scale 
5 
 
RCT. We found that PD-CST was well tolerated and acceptable, with certain modifications, by 
people with PD-MCI/PDD/DLB and their care partners, and that the trial design was feasible 
(reported elsewhere).13 
 
PARTICIPANTS AND METHODS 
The full protocol is published in detail elsewhere.14 
 
Standard protocol approvals, registrations, and patient consents 
The study received favourable ethical opinion from Yorkshire & Humber – Bradford Leeds 
Research Ethics Committee (reference: 15/YH/0531) and was performed in accordance with 
the Declaration of Helsinki and the principles of Good Clinical Practice. The study was 
registered at isrctn.com (registration number ISRCTN11455062). All participants were 
volunteers and provided written informed consent or consultee agreement to participate in the 
study. 
 
Study design and participants 
The INVEST study was a single-blind parallel arm RCT, conducted at seven sites in the UK, 
to explore the impact of CST-PD compared to treatment-as-usual (TAU) on cognitive, 
behavioural, care partner and other dementia-related outcomes in people with PD-
MCI/PDD/DLB and their care partners. Since this was the first time home-based CST adapted 
for this population had been tested and we had no a priori evidence of how the intervention 
would be received, we specifically included participants with different levels of cognitive 
impairment, ranging from MCI to moderate-stage dementia.  
 
We recruited people with PD-MCI/PDD/DLB and their care partners as participant-dyads if 
they met the following inclusion criteria: (1) diagnosis of PD-MCI (Level 1), PDD (probable 
or possible) or DLB (probable or possible) according to standard clinical diagnostic criteria;15-
17 (2) willing and able to participate in the intervention; and (3) on stable medication for at least 
four weeks prior to study entry. Exclusion criteria were: (1) unwilling or unable to participate; 
(2) contact with a care partner three times or less per week; (3) no care partner or companion 
able to participate; (4) living in residential care; (5) unable to understand conversational 
English; and (6) neuropsychiatric complications too severe (i.e. depression, psychosis or 
fluctuating levels of cognitive impairment/delirium) to enable participation in the study (as per 
expert clinicians’ judgement). Care partners were included if they provided care or support for 
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the participant with cognitive impairment and were well enough to be trained to deliver the 
intervention. Care partners were excluded if they were unable to understand conversational 
English, were non-literate or had severe physical illness or dementia (as per self-report and 
performance on the Montreal Cognitive Assessment).18 All PD-MCI/PDD/DLB participants 
(n=76) had the capacity to consent to participation at the start of the trial. During the trial, four 
participants lost the capacity to consent, thus a nominated consultee was appointed enableing 
all four to continue in the study.  
 
Randomisation and blinding 
The Manchester Academic Health Science Centre Clinical Trials Unit, as an independent 
arbiter applied a single-strata, blocked randomisation to CST-PD or TAU at a 1:1 level by 
participant-dyad. Due to the nature of the intervention, dyads were not blind to treatment 
allocation but procedures were in place to conceal the allocation from the independent, blinded 
outcome raters. Following randomisation, the distribution of the tree diagnostic sub-groups 
(PD-MCI, PDD and DLB) was balanced across the two arms with respect to MCI and dementia.   
 
Intervention 
The details of the intervention and how we adapted it to the specific needs of people with PD-
MCI, PDD or DLB is outlined in McCormick et al. 2017a.12 The adaptation process took 
account of several factors, including the cognitive profile (e.g. particular challenges with 
executive function, recall and visuospatial deficits), fatigue and apathy, fluctuating levels of 
attention, motor and general physical frailty of this population. The adapted intervention, CST-
PD, entailed care partner-delivered manual-based individualised CST-based therapy sessions, 
delivered at home for 30 minutes per session, two to three times per week. The activities varied 
in theme and complexity and could be tailored to suit individual needs. The adapted therapy 
manual comprised over 60 topics categorized into nine different themes, with each topic 
containing several cognitively stimulating activities such as discussion topics, word association 
games, and creative tasks. Activities varied in complexity and were matched and adapted to 
suit the needs of the recipient.  The manual itself was paper-based, easy to handle and had large 
accessible print. It was indexed to enable ease of use. All care partners were trained to deliver 
the therapy as intended. The TAU group, which received no additional intervention, provided 
a comparison with the CST-PD group. Any additional non-pharmacological interventions that 
the participants in the TAU group might have received following randomization (e.g.  
physiotherapy, occupational therapy, speech therapy) were noted by the research team.  
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Procedure 
Following consent, participant-dyads underwent a screening period to ensure eligibility. 
Participants meeting inclusion criteria received two to three care partner-delivered CST-PD 
sessions of 30 minutes each or TAU for 12 weeks. Prior to the intervention being delivered, 
care partners in the intervention arm received a two-hour protocol-guided training session of 
CST-PD, delivered in their own homes by a member of the research team. Training included a 
researcher-guided therapy session with the person with PD-MCI/PDD/DLB. The researcher 
completed a protocol training checklist and provided additional training and telephones support 
as needed, based on a skills’ checklist. Assessments took place at baseline and 12-weeks. 
Participants who withdrew from the study before their scheduled assessment visits received an 
early termination assessment. Those experiencing a serious adverse event withdrew from the 
study. Feasibility, acceptability and tolerability evaluations were also undertaken (reported in 
McCormick et al.).13 Assessments for people with PD-MCI/PDD/DLB included: cognition, 
neuropsychiatric symptoms, quality of life, functional ability, relationship satisfaction and 
resilience (Table 1). Care partner assessments were: quality of life, health ratings, relationship 
satisfaction, burden and resilience (Table 1). Care partners in the CST-PD group used diaries 
to report adherence of sessions and 11 participant-dyads completed a semi-structured interview 
to elicit their views and experiences of the intervention. 
 
Outcome measures 
The primary outcomes of the overall INVEST study were tolerability, acceptability and 
feasibility (reported in McCormick et al.).13 Here we report a range of exploratory participant 
and care partner outcomes (see Table 1) including cognition, behaviour, function, quality of 
life and care partner burden and stress.  We also examined aspects of the dyadic relationship, 
resilience and empathy. All rated outcomes were undertaken by highly trained research nurses 
with extensive experience in dementia and PD-related research. Additionally, qualitative 
outcomes using observational data from participant-dyad diaries, completed after each therapy 
session, and semi-structured interviews, in a sub-sample of the CST-PD group were also 
included.  
 
‘Feasibility’ included a detailed evaluation of eligibility, recruitment and retention rates, 
overall trial design (the degree to which the protocol balanced scientific and practical 
considerations), willingness to be randomised, blinding procedures and data collection (i.e. 
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timing, quality, acceptability). ‘Acceptability’ was the extent to which the participant-dyads 
considered the intervention ‘appropriate’ (i.e. care partner’s perceptions of the recipient’s 
interest, motivation and sense of achievement following each therapy session) and the ability 
of recipients endure the intervention (i.e. adverse event rate).   
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Table 1 Outcome measure descriptions. 
   Respondent 
Outcome 
domain 
Specific measurement tool Description of the tool  Person 
with PD-
MCI/PDD
/DLB 
Care 
partners 
Cognition The Addenbrooke’s Cognitive Examination 
(ACE-III) a 19 
Global cognition (total score) and cognitive sub-
domains of memory, attention, verbal fluency, 
language and visuospatial function.  
✓  
The Dementia Cognitive Fluctuation Scale 
(DCF) b 20 
Fluctuations in person with PD-MCI/PDD/DLB 
cognition reported by the care partner. 
✓  
(proxy) 
 
Functional 
ability 
The Pill questionnaire b 21 The ability to undertake a specific activity of 
daily living (i.e. medication intake). 
✓  
Quality of 
life 
The Parkinson’s Disease Questionnaire-39 
(PDQ-39) b 22 
Parkinson’s-specific quality of life. ✓  
The EuroQoL-5D (EQ5D) a 23 Health-related quality of life. ✓ ✓ 
Neuropsychi
atric 
symptoms 
(NPS) 
The Neuropsychiatric Inventory (NPI) b 24 Presence and magnitude of ‘clinically 
significant’ (frequency x severity ≥4) of NPS 
sub-domains reported by the care partner.  
✓  
(proxy) 
 
The Hospital Anxiety and Depression Scale 
(HADS) b 25 
Self-rated anxiety and depression. ✓ ✓ 
The Lille Apathy Rating Scale (LARS) b 26 Self-rated apathy. ✓  
Health The Short Form-12 Health Survey (SF-12) a 27 General physical and mental health.  ✓ 
Relationship 
quality 
The Relationship Satisfaction Scale (RSS) a 28 Satisfaction with the dyadic relationship. ✓ ✓ 
The Dyadic Relationship Scale (DRS) a,b 29 Positive dyadic interaction and negative strain.  ✓ 
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The Family Caregiving Role Scale (FCR) a,b 30 Specific feelings associated to care provision.  ✓ 
Burden The Zarit Burden Interview (ZBI) b 31 Burden related to care provision.  ✓ 
The Relatives’ Stress Scale (Rel.SS) b 32 Stress related to care provision.  ✓ 
Resilience The Brief Resilience Scale (BRS) a 33 The ability to bounce back in stressful situations.  ✓ ✓ 
Empathy The Interpersonal Reactivity Index (IRI) a 34 Empathic tendencies and perspective taking. ✓  
Notes: a Higher scores better; b Higher scores worse.
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Sample size  
We based our sample size calculation on previous studies,35 and took a conservative approach, 
estimating the standardised effect size on cognition to be 0.4. As this was a pilot feasibility 
trial, we chose a one-sided test and a less stringent significance level of 0.2 to avoid missing a 
promising effect. Thus, assuming 80% power and a correlation coefficient of 0.5 between 
baseline and endpoint on cognitive outcomes, the required sample size was 27 completers per 
group. By enrolling 32 dyads per group, it allowed for a 15% attrition rate. For the secondary, 
exploratory outcomes, the proposed sample size of 27 per group was within the recommended 
guidelines (24–50 participants35,36) required to estimate the SD for a sample size calculation. 
Since the attrition rate was higher than expected during the first year of recruitment (28%), we 
obtained ethical approval to enrol 38 dyads per group to maintain the target number of 
completers. 
 
Data analysis 
Since this was an exploratory trial of a new complex intervention, we agreed a priori to 
interpret the results with caution. Thus, although we undertook initial inferential statistics and 
hypothesis testing, our goal was to uncover any important potential associations in the study 
variables.37 For this reason, we evaluated statistical significance at the 0.2 level using a one-
sided test. Specifically, we explored changes in measures between the two groups (CST-PD 
and TAU) over time using ANCOVA, controlling for baseline values. All analyses were 
conducted on an intention-to-treat basis, on complete case data. For the qualitative analysis, 
using NVivo 11 software38, data from participant-dyad diaries, researcher field notes, and semi-
structured interviews were used. We triangulated the results of our quantitative findings with 
thematic analysis.39 Using an inductive process, we systematically extracted codes from each 
data source to derive key themes; these were subsequently triangulated with the quantitative 
outcome to establish correspondence between the qualitative and qualitative data. We arrived 
at the final themes by consensus of five INVEST investigators (IL, SV, SM, SS and BK). 
 
RESULTS 
The 76 recruited participant-dyads were randomised to either the CST-PD (n=38) or the TAU 
group (n=38) following randomisation (Figure 1). Characteristics of participant-dyads are 
outlined in Table 2. Twenty-one per cent (n=16) of participants with PD-MCI/PDD/DLB were 
female and all were native English speakers. Diagnoses included 19.8% (n=15) PD-MCI, 
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52.6% (n=40) PDD, and 27.6% (n=21) DLB. Of the care partners, 89% (n=68) were female, 
and 77.6% (n=59) were spouses or live-in partners and 17.1% (n=13) were adult children. The 
remaining four care partners included a grandchild, a friend, a live-in carer and a divorcee. Of 
those randomised, 72% completed the full study protocol.  
 
Baseline demographics revealed a relatively good case mix between the two arms, with only 
education and diagnosis seeing a slight imbalance (see Table 2). Descriptive statistics of the 
outcome measures at baseline are presented in Table 2. There were also some imbalances in 
baseline outcome scores between the two arms, suggesting randomisation was not fully 
successful, possibly due to the small sample size. We avoided any potential bias by controlling 
for baseline scores in the analysis. No cognitive enhancing medications were changed during 
the course of the study. 
 
Preliminary analysis compared the effect of treatment allocation and baseline characteristics of 
subjects with and without complete data at follow-up using a logistic model for each outcome. 
Differential missingness was observed in the treatment arms, with a higher proportion of 
missing data in the intervention arm. For the primary outcome, data were missing for 21 
individuals, 6 (29%) in the control arm and 15 (71%) in the intervention arm. We found no 
differential missingness conditional on the participant characteristics; thus, we proceeded with 
the main analysis under the ‘missing at random’ assumption. 
 
A total of 56 participant-dyads completed the study, 24 in the CST-PD group and 32 in the 
TAU group. Using ANCOVA to model group differences of change in cognition at 12 weeks 
by adjusting for baseline scores, global cognition (ACE-III) improved by 1.7 on average in the 
CST-PD group compared to the TAU group; however, this difference was not statistically 
significant [Adjusted mean difference (AMD) = 1.7, Cohen’s d = 0.38, p = 0.227]. The results 
of the exploratory measures revealed a number of potential changes in outcomes for both 
intervention recipients and care partner groups and are presented in Table 3. For intervention 
recipients, the CST-PD group had statistically lower scores on the verbal fluency sub-scale of 
the ACE-III (AMD = -0.74, d = 0.35 , p = 0.134), higher scores on the Neuropsychiatric 
Inventory (NPI) total signalling greater symptoms (AMD = 4.46, d = 0.42, p = 0.049), as well 
as the proportion of ‘clinically significant’ (FxS score ≥ 4) and ‘clinically present’ NPI (FxS 
score >1) scores (AMD = 0.05, d = 0.35, p = 0.078; AMD = 0.05, d = 0.25, p = 0.173, 
respectively), the Brief Resilience Scale (AMD = -1.17, d = 0.12, p = 0.174), and the 
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Perspective Taking subscale of the Interpersonal Reactivity Index (AMD = -1.32, d = 0.03, p 
= 0.082). Conversely, for the care partner sample, CST-PD resulted in statistically significant 
improvements compared to TAU on quality of life [EuroQol index (AMD = 0.08, d = 0.16, p 
= 0.048) and visual analogue scale measures (AMD = 4.76, d = 0.07, p = 0.104)], burden and 
stress [Zarit Burden Interview (AMD = -2.24, d = 0.16, p = 0.193), and the Relatives’ Stress 
Scale (AMD = -1.75, d = 0.05, p = 0.160), respectively] and relationship quality [Relationship 
Satisfaction Scale (AMD = 3.46, d = 0.01, p = 0.020), and the Dyadic Relationship Scale 
positive interaction subscale (AMD = 1.76, d = 0.55, p = 0.015)]. In contrast, care partners in 
the CST-PD group reported a significant increase in anxiety symptoms measured by the HADS 
(AMD = 1.03, d = 0.30, p = 0.112). Adherence data, retention and integrity of blinding (for 
details see elsewhere)13 revealed that over two thirds of participants in the CST-PD group 
received the recommended dose of at least 60 minutes of therapy per week. 
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Figure 1 CONSORT 2010 Flow Diagram 
  
Interviewed (n=0) 
Assessed for eligibility (n=76) 
Interviewed (n=10) 
Completed follow-up (n=24) 
Lost to follow-up (n=4) 
 Did not wish to continue (n=3) 
 Hospitalisation (n=1) 
  
Discontinued intervention (give reasons) (n=  ) 
Allocated to therapy arm (n=38) 
 Received allocated therapy (n=28) 
 Did not receive allocated therapy (n=10) 
  Hospitalisation (n=1) 
  Did not wish to continue (n=4) 
  Poor health (n=1) 
  Participation in conflicting group (n=1) 
  Care partner poor health (n=1) 
  Lost contact (n=2) 
Completed follow-up (n=32) 
Lost to follow-up (n=3) 
 Did not wish to continue (n=1) 
 Hospitalisation (n=2) 
 
Allocated to control arm (n=38) 
Remained during therapy period (n=35) 
Discontinued during therapy period (n=3) 
  Hospitalisation (n=1) 
Did not wish to continue (n = 2) 
 
ALLOCATION 
INTERVIEW 
FOLLOW-UP 
Randomized (n=76) 
ENROLMENT 
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Table 2 Baseline demographic and clinical variables in the active intervention (CST-PD) and control (TAU) groups.  
 
 
Demographics and other variables 
 
People with PD-MCI/PDD/DLB (n = 76) 
 
 
Care partners (n = 76) 
Control Intervention 
 
Control Intervention 
Categorical variables n % N % n % n % 
Gender Female 8 21.05 8 21.05 35 92.11 33 86.84 
Male 30 78.95 30 78.95 3 7.89 5 13.16 
Ethnicity White 35 92.11 36 94.74 35 92.11 35 92.11 
Non-white 2 5.26 2 5.26 2 5.26 3 7.89 
Did not specify 1 2.63 0 0.00 1 2.36 0 0.00 
Education level   Up to 18 year old schooling 22 57.89 18 47.37 20 52.63 17 44.74 
Further education and higher 16 42.11 20 52.63 18 47.37 21 55.26 
Marital status  Single 6 15.79 6 15.79 7 18.42 6 15.79 
Married/ Partnership 32 84.21 32 84.21 31 81.58 32 84.21 
Living status   Alone 5 13.16 1 2.63 2 5.26 0 0.00 
With others 33 86.84 37 97.37 36 94.74 38 100.00 
Diagnosis PD-MCI 8 21.05 7 18.42     
PDD 18 47.37 22 57.89     
DLB 12 31.58 9 23.68     
Relationship Spouse/ partner     28 73.68 31 81.58 
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Son/daughter     9 23.68 4 10.53 
Other     1 2.63 3 7.89 
Caregiving 
weekly hours 
(Up to an 
average of) 
1 hour per day     10 26.32 5 13.16 
8 hours per day     9 23.68 13 34.21 
24 hours a day 
    19 50.00 20 52.63 
 
Continuous variables 
 
n 
Median;  
IQR [range] 
n 
Median;  
IQR [range] 
n 
Median; 
 IQR [range] 
n 
Median;  
IQR [range] 
Age, years 
38 
75; 72-81 [61-
90] 
38 
74.50; 68-77 
[55-84] 
38 
68.50; 59-72 
[43-85] 
38 
67; 59-71  
[21-88] 
Dyad known, years 
    29 
50; 43-56 
 [3-68] 
34 
46; 30-52 [0.5-
70] 
Caregiving, years 
    38 
2.50; 1-6  
[0-15] 
38 
3.25; 1.5-8 
 [0-20] 
Montreal Cognitive Assessment (MoCA) 
35 
19; 15-22  
[7-24] 
36 
17.5; 15-21.5  
[8-30] 
    
Schwab-England score 
37 
60; 35-80  
[10-100] 
37 
60; 30-70  
[10-90] 
    
UPDRS motor score 
38 
 34; 17.50-40.25 
[9-69] 
37 
24; 18-38  
[8-58] 
    
Duration of clinical symptoms, years 
38 
5.5; 2-10  
[0-33] 
38 
4; 2-10.50  
[0.5 –24] 
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Baseline variables n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
Cognition ACE-III total 36 63.78 (15.15) 35 68.69 (14.73)     
Attention 36 13.06 (2.78) 35 13.23 (2.52)     
Memory 36 14.22 (5.17) 35 15.91 (5.87)     
Verbal Fluency 36 4.69 (2.64) 35 6.23 (3.21)     
Language 36 20.92 (4.04) 35 22.37 (3.05)     
Visuospatial 36 10.89 (3.76) 35 10.94 (3.20)     
Dementia Fluctuation scale 35 10.56 (3.61) 35 12.46 (3.80)     
Function Pill questionnaire 34 1.74 (1.02) 34 1.76 (1.10)     
Quality of life PDQ-39 27 28.88 (14.48) 28 39.13 (17.18)     
EuroQoL-index 36 0.58 (0.33) 35 0.50 (0.34) 36 0.84 (0.19) 35 0.77 (0.27) 
EuroQoL-VAS 36 68.42 (18.57) 35 61.34 (14.97) 35 78.03 (15.11) 35 73.77 (16.99) 
Neuropsychiatric 
symptoms 
NPI Total 34 14.50 (14.71) 35 18.37 (15.20)     
NPI % clinically significant ≥4 36 18% (0.24) 35 22.57% (0.21)     
NPI % presence/absence 36 36% (0.25) 35 40.29% (0.22)     
NPI Care partner distress     34 7.03 (7.29) 35 9.06 (8.82) 
HADS anxiety 31 6.65 (4.22) 31 8.07 (4.78) 35 5.11 (4.22) 35 6.20 (4.54) 
HADS depression 34 6.35 (3.03) 34 6.50 (2.91) 35 3.74 (3.82) 35 4.77 (4.19) 
LARS 34 -14.24 (9.02) 33 -15.58 (8.30)     
Health rating SF-12 physical health     35 51.80 (8.81) 35 47.81 (11.95) 
SF-12 mental health     35 49.14 (10.66) 35 46.36 (13.15) 
RSS 32 34.13 (8.28) 32 32.81 (7.83) 36 31.67 (9.11) 35 26.51 (11.72) 
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Relationship 
satisfaction 
DRS positive interaction     31 9.74 (3.79) 34 9.56 (3.41) 
DRS negative strain     30 10.80 (3.24) 31 9.94 (3.43) 
FCR satisfaction 36 3.95 (0.60) 35 4.08 (0.56)     
FCR resentment 36 2.34 (0.99) 35 2.46 (1.09)     
FCR anger 36 1.72 (0.72) 35 1.96 (0.83)     
Burden ZBI     35 30.06 (16.21) 30 34.90 (18.01) 
Rel.SS     35 20.80 (11.87) 35 23.37 (11.51) 
Resilience BRS 33 19.73 (4.57) 34 18.91 (4.52) 36 23.53 (5.28) 35 21.69 (4.82) 
Empathy IRI total of 2 sub-scales 33 24.48 (3.99) 33 24.21 (4.96)     
 
Abbreviations: ACE-III – Addenbrooke’s Cognitive Evaluation; BRS – Brief Resilience Scale; DLB – Dementia with Lewy bodies; DRS – Dyadic Relationship 
Scale, positive interaction or negative strain sub-scale; EQ5D – EuroQoL-5D index or visual analogue scale (VAS); FCR – Family Caregiving Role scale; 
HADS – Hospital Anxiety and Depression Scale;  IQR – interquartile range; IRI – Interpersonal Reactivity Index; LARS – Lille Apathy Rating Scale; MoCA 
– Montreal Cognitive Assessment; NPI – Neuropsychiatric Inventory; PDD – Parkinson’s disease dementia; PD-MCI – Parkinson’s disease and mild cognitive 
impairment; PDQ-39 – Parkinson’s Disease Questionnaire; PD-MCI/PDD/DLB – Parkinson’s-related dementia; Rel.SS – Relatives’ Stress Scale;  RSS – 
Relationship Satisfaction Scale; SD – standard deviation; SF-12 – Short Form 12 Health Survey; ZBI – Zarit Burden Interview. 
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Table 3 Exploratory results for participant-dyads in the two arms showing the difference between baseline and 12 weeks. 
 Control 
 
Intervention    
People with PD-MCI/PDD/DLB 
 
 
n 
 
Mean (SD) 
 
n 
 
Mean (SD) 
Adjusted mean 
difference* 
(Intervention –
Control) 
80% 
Confidence 
interval limit† 
P 
value‡ 
Cognition ACE-III total a 32 62.84 (18.44) 24 69.39 (14.99) -1.70 >-3.62 0.227 
Attention 32 12.53 (3.28) 24 13.52 (2.57) 0.48 >-0.01 0.206 
Memory 32 14.22 (6.31) 24 16.70 (5.17) 0.46 >-0.33 0.311 
Verbal Fluency 32 4.97 (3.38) 24 6.17 (3.49) -0.74 <-0.18 0.134 
Language 32 20.69 (4.91) 24 22.57 (2.33) -0.25 >-0.97 0.388 
Visuospatial 32 10.44 (3.78) 24 10.43 (3.74) -0.34 >-0.87 0.298 
Dementia Fluctuation scale b 32 10.97 (3.57) 24 11.57 (3.90) -0.37 >-0.97 0.303 
Functional 
ability 
Pill questionnaire b 32 2.06 (1.01) 24 1.96 (1.30) -0.05 >-0.30 0.435 
Quality of life PDQ-39 b 23 29.31 (13.74) 17 38.29 (13.39) 0.91 >-1.66 0.382 
EuroQoL-index a  32 0.57 (0.32) 24 0.57 (0.32) 0.05 >-0.01 0.241 
EuroQoL (VAS) a 31 62.35 (22.22) 24 62.30 (17.94) 1.75 >-2.69 0.370 
Neuropsychiat
ric symptoms 
NPI Total b 32 9.88 (8.88) 24 15.04 (16.06) 4.46 >2.21 0.049 
NPI clinically significant 32 0.11 (0.14) 24 0.17 (0.19) 0.05 >0.02 0.078 
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NPI presence/absence 32 0.33 (0.24) 24 0.38 (0.22) 0.05 >0.01 0.173 
HADS anxiety b 29 5.66 (3.92) 20 6.75 (3.51) 0.24 >-0.44 0.382 
HADS depression b 30 5.33 (3.58) 20 5.25 (2.55) 0.28 >-0.12 0.367 
LARS b 28 -13.96 (9.55) 18 -16.56 (7.56) -1.62 >3.34 0.215 
Relationship 
satisfaction 
RSS a 30 35.20 (7.02) 24 32.48 (9.69) -1.25 >-3.13 0.288 
Resilience BRS a 29 20.97 (5.18) 21 20.33 (4.89) -1.17 >-2.22 0.174 
Empathy IRI Empathic concern a 29 25.76 (3.43) 21 25.71 (3.02) -0.06 >-0.79 0.475 
IRI Perspective takinga 29 25.10 (3.84) 21 24.38 (3.37) -1.32 <-0.53 0.082 
 
Care partners 
 
       
Quality of life EuroQoL-index a 31 0.79 (0.22) 24 0.82 (0.14) 0.08 >0.04 0.048 
EuroQoL-VAS a 32 75.16 (18.42) 24 76.52 (19.03) 4.76 >1.59 0.104 
Person with 
PD-
MCI/PDD/DL
B NPS 
NPI – Care partner distress b 32 5.28 (4.64) 24 7.48 (8.27) 2.11 >0.94 0.066 
Neuropsychiat
ric symptoms 
HADS anxiety b 32 5.38 (4.91) 24 6.78 (4.33) 1.03 >0.32 0.112 
HADS depression b 32 4.34 (3.84) 24 4.91 (4.10) 0.35 >-0.30 0.326 
Health rating SF-12 physical health a 32 49.79 (12.08) 24 47.31 (10.26) 1.91 >-0.24 0.228 
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SF-12 mental health a 32 46.85 (13.09) 24 49.14 (10.66) 1.89 >-0.58 0.260 
Relationship 
satisfaction 
RSS a 32 30.25 (8.08) 22 30.18 (11.24) 3.46 >2.07 0.020 
DRS positive interaction a 30 8.53 (2.99) 24 10.30 (3.53) 1.76 >1.10 0.015 
DRS negative strain b 30 10.27 (2.97) 22 9.77 (3.73) 0.23 >-0.41 0.380 
FCR satisfaction a 32 3.91 (0.48) 24 3.89 (0.73) -0.09 >-0.20 0.225 
FCR resentment b 32 2.55 (1.10) 22 2.65 (0.94) 0.04 >-0.13 0.417 
FCR anger b 32 1.95 (1.14) 24 1.97 (0.83) -0.08 >-0.27 0.358 
Burden ZBI b 30 30.47 (15.06) 22 32.91 (16.07) -2.24 <-0.07 0.193 
Rel.SS b 31 22.16 (12.29) 21 22.81 (11.39) -1.75 <-0.27 0.160 
Resilience BRS a 32 22.63 (5.25) 24 21.31 (5.01) 0.12 >-0.65 0.447 
Notes: * Adjusted for baseline outcome value; † One sided confidence interval provides the (upper or lower) limit of range of plausible values of 
point estimate; ‡ Significance level 0.2; a Higher scores better; b Higher scores worse 
Abbreviations: ACE-III – Addenbrooke’s Cognitive Evaluation; BRS – Brief Resilience Scale; DRS – Dyadic Relationship Scale, positive 
interaction or negative strain sub-scale; EQ5D – EuroQoL-5D index or visual analogue scale (VAS); FCR – Family Caregiving Role scale; HADS 
– Hospital Anxiety and Depression Scale;  IRI – Interpersonal Reactivity Index; LARS – Lille Apathy Rating Scale; MoCA – Montreal Cognitive 
Assessment; NPI – Neuropsychiatric Inventory; PDQ-39 – Parkinson’s Disease Questionnaire; PD-MCI/PDD/DLB – Parkinson’s-related 
dementia; Rel.SS – Relatives’ Stress Scale;  RSS – Relationship Satisfaction Scale; SD – standard deviation; SF-12 – Short Form 12 Health Survey; 
ZBI – Zarit Burden Interview. 
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Qualitative evaluation 
Synthesis of qualitative data elicited six themes presented in Table 4 together with the 
corresponding outcome domain related to each theme, and example extracts supporting each 
theme. Overall findings suggest “in the moment” enjoyment of CST-PD (Enjoyment/Fun). In 
addition, consistent with quantitative data regarding efficacy outcomes, the qualitative data 
suggest participants experienced improvements in cognition, with subsequent impact on 
communication and conversation with care partners (Communication/Cognition). The findings 
regarding physical and mental abilities suggested that while for some participants CST-PD 
afforded the opportunity to demonstrate retained abilities, for others the intervention 
highlighted changes and loss. The care partner outcomes indicated that CST-PD provided 
opportunities for conversation and reminiscence that would not have otherwise have occurred 
(Interpersonal relationships), although some degree of challenge and burden regarding the 
delivery of the CST sessions was reported by three care partners (Care partner aspects). 
 
Table 4 Key themes emerging from the semi-structured interview with participant-dyads. 
Theme Outcome 
Domain 
Quote  
Enjoyment/ 
fun 
Quality of 
Life/ 
Health 
C: Everything you try gives you a different insight into things, 
doesn’t it, and we’ve so enjoyed talking, haven’t we? P: Yeah, it 
produces a feeling of, uh, wellbeing, doesn’t it? C: It does, yeah, 
gets the endorphins. [Patient and Care partner, CS12, interview] 
You know, it’s just enjoyable and it just gives you that chance to 
come outside of all your problems…just sit down and have a 
laugh. [Care partner, CS12, interview] 
It was almost like when he was back in work, brainstorming and 
getting involved and feeling valued where I think a lot in life 
now where you just plodding through every day, you don’t feel 
the value, you don’t feel that your opinions are valued and I think 
for the first time in a long time I think he felt valued or that his 
experiences were meaningful. [Care partner, CS9, interview] 
Communicati
on / Cognition 
Cognition [Liked] seeing [name] exercising his analytical skills, making 
intelligent observations. [Care partner, CS18, interview] 
We’d got quite uncommunicative not intentionally but it had just 
happened and it’s been lovely sometimes even the picture has, 
[husband’s name] has started talking about it before I‘ve suggest 
anything. [...] It's like getting him back again, which is good. 
[Care partner, CS11, interview] 
When we open a new, a new chapter, a new scene, I’m, I’m 
starting to think more structured and I’m thinking, you know, 
well this is going to be what it is, why is it, what’s, I’m starting 
to prepare thought processes before we, we actually read the 
information and because, and it’s going to be questions on every 
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one, it’s keeping my brain ticking over a bit further. [Patient, 
CS12, interview] 
Behavioural 
features 
Neuropsyc
hiatric 
Symptoms 
I didn’t expect the reaction from dad, so the fact that he was so 
interested and so wanting to take part and be helpful. [Care 
partner, CS9, interview] 
He didn’t sort of show joy or you know anxiety or none of them. 
[Care partner, CS13, interview] 
Interpersonal 
relationships 
Relationshi
p Quality/ 
Empathy 
[Our granddaughter] done a session with him, and that was quite 
interesting to see the banter between them, between the young 
and the old and interacting and she was very good at it, very 
good, and he responded well, that was a really fun one really. 
[Care partner, CS13, interview] 
Togetherness, reminiscing, good conversation, good topic. [Care 
partner, CS7, diary] 
P: It's doing the best we can to keep our brains active.  I think 
that, that’s the key and… C: Yeah, and also to take from me the 
caring side, because it was a joint thing, wasn’t it?  It was a joint 
enjoyable thing, rather than, you know, um, uh, a task or 
something, you know, that had to be done.  [Patient and Care 
partner, CS12, interview] 
Physical and 
mental 
abilities 
Functional 
Ability 
Well he can’t write and he struggled with drawing. [...] He 
struggled with initiating to answer. [Care partner, CS19, 
interview] 
[He] was very good at being systematic and getting a list of 
things and getting the book opened, you know, and maybe a lot 
of people will not be able to do that, you know maybe he was 
very proactive. [Care partner, CS3, interview] 
He really wanted to do it because he really wanted to show what 
he could do. [Care partner, CS9, interview] 
Reminded him of his disability and not being mobile enough to 
visit these places on his own. [Care partner, CS5, interview] 
Care partner 
aspects 
Resilience/ 
Burden 
I didn’t feel it was fun, it was something else for me to get [my 
husband] to participate. [...] I felt I had to do it. [Care partner, 
CS4, interview] 
We did enjoy when my sister and her husband came around, and 
that session, you know…I find that the effort, the weight was 
taken off my shoulders [my husband] engaging with the other 
person more than he was engaging with me. [...] I just thought 
that he had such a great time [with other people], it was so 
enjoyable for him, whereas it was much of a chore when you 
were doing it with me. [Care partner, CS4, interview] 
Abbreviations: C- care partner; P – person with Parkinson’s-related dementia.
24 
 
DISCUSSION  
This is the first randomised controlled feasibility trial of a CST-based intervention specifically 
adapted for people with Parkinson’s-related MCI or dementia (PDD/DLB), and is the largest 
study of its kind to date. It thus makes a valuable contribution to the emerging field of non-
pharmacological interventions for cognition and other dementia-related outcomes in this 
population. The CST-PD programme retains the core principles of the already well-established 
CST, but is specifically tailored to the needs of people with a complex form of dementia 
characterised by motor and other physical problems. The preserved CST features include 
positive discussion, enjoyable activities, affection, supportive feedback and a focus on opinions 
rather than facts. Critical modifications included removing motor-dependent activities, 
potentially hallucinogenic or unclear images and updating manual content by increasing the 
usability of the format.12 The ability to tailor the intervention to specific needs and preferences 
of the participants enabled us to offer successfully the intervention to people with a wide range 
of cognitive abilities and interest, without the risk of the intervention not being challenging 
enough. Furthermore, we designed CST-PD to be a home–based, individualised, care partner-
delivered intervention, which strengthened the dyadic relationship of the person and their care 
partner, which is key in predicting positive outcomes of home-based care.40,41 
 
We have already demonstrated the feasibility of conducting such a study in this population, as 
well as it being an acceptable and well tolerated intervention in people with PD-
MCI/PDD/DLB and their care partners.13  Here, our exploratory analysis of potential efficacy 
outcomes in the intervention recipients indicated improvements for cognition overall, but did 
this did not reach statistical significance. This is consistent with a previous study of 
individualised CST (iCST) in people with other forms of dementia,8 but not group CST studies 
in non-PD groups demonstrating significant improvement in cognition.7,42,43 It is possible that 
the imbalance in the education level of the two experimental arms may have impacted on this, 
as the participants in the CST-PD arm had a lower education level compared to those in the 
TAU group. A potential mechanism for improvement in cognition with this type of intervention 
could be the activation of compensatory mechanisms of synaptic plasticity.44 As suggested by 
the original study of iCST in non-PD dementia,8 it is possible that a higher dose of therapy is 
needed to impact cognition. In our study, the average dose was 1.76 (SD = 0.72) per week,13 
and this may not have been high enough. Higher intervention doses of cognitive rehabilitation 
have been shown to beneficial in very early stage cognitive impairment in PD.45 This is despite 
previous suggestions that in non-PD dementia cognitive benefits can be seen with twice weekly 
25 
 
sessions of CST.46 The added burden of physical disability and PD-associated fatigue and 
apathy may further hinder any potential benefit and necessitate an even higher dose. 
 
Contrary to expectation, informant-rated behavioural outcomes assessed with the NPI appeared 
to worsen in the CST-PD group. This included the apathy domain, which has been shown to 
improve with intensive cognitive rehabilitation in early stage cognitive impairment in PD.45 It 
is likely that the additional time spent with the therapy recipient through undertaking the 
therapy may have highlighted previously unrecognised behavioural and psychiatric symptoms 
(BPSD), resulting in higher informant ratings across a range of symptoms, or that the slight 
imbalance in diagnostic sub-types across the two treatment arms may have played a role. 
However, it is important to note that no participants were withdrawn due to worsening of BPSD 
and BPSD were not reported as adverse events in the qualitative data.13 Although the direction 
of these results suggests a potentially harmful intervention, they should be interpreted with 
caution since we purposely chose a high significance level to capture any potential effects 
increasing probability of Type I errors. Combined with the exploratory multiple comparisons, 
we may be observing false positives. Furthermore, the behavioural outcomes were not mirrored 
in the qualitative reports, which revealed positive, ‘in the moment’ experiences in cognition, 
behaviour and function immediately following therapy sessions.  
 
In contrast to the clinical outcomes in the participants with PD-MCI/PDD/DLB, care partners 
experienced improvements in several outcomes. This is crucial considering that caregiving in 
this population is complex, and care burden is best described as a multidimensional construct47 
that has a significant negative effect on a care partners’ quality of life, health and 
relationships,48-50  in effect creating ‘hidden or invisible patients.51 Specially, care partners in 
the CST-PD group reported reduced care burden and stress, improved quality of life, and 
enhanced relationships with the individual with PD-MCI/PDD/DLB. This finding is 
particularly striking since in previous work, care partners rated relationship quality lower than 
people with dementia.52 It also supports and extends the results of the original iCST study, 
which found that quality of life in care partners improved and that individuals with dementia 
regarded the care relationship more positively.8 Maintaining a positive caring relationship and 
ensuring care partner health and wellbeing is essential to delay or prevent long-term care for 
people with PD-MCI/PDD/DLB,39,53 slow progression of cognitive and functional decline,54 
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and lower care partner burden.55 It may also lower costs of providing care, and reduce length 
of hospitalisation and rate of crisis interventions.56,57 
 
The intervention had no observable effects on either ‘resilience’ or ‘empathy’; however, this 
was not surprising considering the relatively small sample size of this pilot study and that it 
was not powered to detect differences on these variables. Resilience, measured with the Brief 
Resilience Scale (BRS), assesses the ability to bounce back or recover from stress and consists 
of six items scored using a 5-point Likert scale. Empathy, measured with the Interpersonal 
Reactivity Index (IRI), encompasses two aspects: empathic concern and perspective taking, 
each measured on a Likert scale. These are important as they may reflect aspects of the apathy 
syndrome, which is closely linked with cognitive impairment/dementia in PD. We also saw no 
significant changes in apathy scores. 
 
A potential limitation of our study is the heterogeneity of the diagnoses of the participant group. 
We purposefully included the three groups, as this feasibility study was an initial exploration 
of the appropriateness of the intervention across the range of cognitive impairment within the 
Lewy body spectrum. However, the heterogeneity renders the findings difficult to interpret and 
future trials should aim to limit inclusion to a single group or those with PDD/DLB only. 
 
In conclusion, this study, although a pilot exploratory trial, has provided invaluable data to 
progress the emerging field of psychosocial interventions for PD-MCI/PDD/DLB as well as 
contributed to the literature on dyadic psychosocial interventions. It strongly supports a role 
for care partner-delivered interventions through the mechanism of supporting care partner 
health and wellbeing, as well as strengthening relationship quality. A full scale trial is now 
warranted to establish clinical effectiveness. 
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